FDA said it is temporarily halting its risk evaluation and mitigation strategy (REMS) program for clozapine, a treatment for schizophrenia.

In the ongoing aftermath of the opioid crisis, it’s common for physicians to attempt to wean some patients off opioids in favor of alternative means of pain management. But while the goal is increased safety for the patient, opioid tapering does not come without risks. A recent study in JAMA found a significant association between opioid dose tapering and both overdose and mental health crises.

A recent study published in Nature Reviews Endocrinology sheds light on the debate about acetaminophen use for pregnant women. After reviewing the medical literature on the topic going back 25 years, the research team is urging caution on the use of this common OTC during pregnancy because of the strong link associated with adverse neurological, urogenital, and reproductive outcomes in children.

Over the past few years, blood pressure medications have been recalled due to concerns about N-nitrosodimethylamine (NDMA), a probable carcinogen. But this may not be the only impurity to be worried about in these medications. As drug companies have addressed the NDMA issue, they have also found new potentially dangerous chemicals known as azido impurities.